… 1 or bioconversion 2 to activate soluble guanylate cyclase (sGC). However, the use of such
compounds is limited by a potential lack of response due to insufficient biometabolism 3 , …

… therapeutic potential. Intravenous YC-1 produced a significant reduction of mean arterial
pressure in a rat model of hypertension. Oral BAY 41–2272 and BAY 41–8543 also produced …

… The search continues for safe and effective agents that improve outcomes when added to
standard therapy. The nitric oxide (NO)—soluble guanylate cyclase (sGC)—cyclic guanosine …

… These findings support future investigation into the therapeutic potential of CRD-733 in human
heart failure [85,86,87]. Inhibition of brain PDE9 may improve synaptic plasticity, behavior; …

… The heterodimeric haemoprotein soluble guanylate cyclase (sGC) acts as the principal …
considerable therapeutic potential. Yet sGC can hardly be described as a novel therapeutic target…

… -bound guanylate cyclase-C (GC-C) receptors lining the GI tract may serve as novel therapeutic
… Studies of the GC-C paracrine signalling axis have revealed the therapeutic potential of …

… are currently ongoing to fully exploit the therapeutic potential of cGMP increase. Recently,
NO-… stimulators could have an even broader therapeutic potential beyond PH and HF. Within …

… Nitric oxide (NO) is a gasotransmitter that binds to soluble guanylate cyclase (sGC) to
produce cyclic guanosine monophosphate (cGMP). Impairment of this pathway has been …

… Asn757Lysfs*2) and fully abrogates the guanylate cyclase catalytic domain. … The advances,
from understanding a pathogenic toxin to a new drug class with many potential therapeutic …

… therapeutic potential for sGC stimulators in lung diseases was clearly demonstrated. However,
the sGC stimulators have potential … to study the therapeutic potential of sGC stimulators …